SCHEMBL331296

SCHEMBL331296

COc1ccc(C(=O)C=Cc2ccccc2OC)c(O)c1

nearest known ligand 0.83

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR1H4 Q96RI1 3/20 0.83
MAPT P10636 4/20 0.81
NPC1 O15118 2/20 0.81
RAB9A P51151 2/20 0.81
MEN1 O00255 2/20 0.81
MAPK1 P28482 2/20 0.81
KMT2A Q03164 2/20 0.81
ABCG2 Q9UNQ0 6/20 0.75
APP P05067 3/20 0.74
AR P10275 3/20 0.73
MAOB P27338 2/20 0.73
LMNA P02545 2/20 0.70
RECQL P46063 1/20 0.70
ATM Q13315 1/20 0.70
L3MBTL1 Q9Y468 1/20 0.70
PTPN1 P18031 1/20 0.68
FLT3 P36888 1/20 0.65
CHRNA7 P36544 1/20 0.65
CYP3A4 P08684 1/20 0.65
CYP2C19 P33261 1/20 0.65

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL633204 1.00 NR1H4 (0.83) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL4046466 0.91 NR1H4 (1.00) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL4046463 0.91 NR1H4 (1.00) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL5139199 0.90 NR1H4 (0.83) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL5139197 0.90 NR1H4 (0.83) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL634358 0.89 MAPT (1.00) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL21527677 0.89 ABCG2 (0.79) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL21527676 0.89 ABCG2 (0.79) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL29443580 0.89 MAPT (0.82) NR1H4MAPTNPC1RAB9AMEN1
SCHEMBL634357 0.89 MAPT (1.00) NR1H4MAPTNPC1RAB9AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3562803-B1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2025-10-15 EP claimed
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2021-11-25 US claimed
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-11-07 US claimed
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA UNIV DEGLI STUDI ROMA LA SAPIENZA (IT) 2021-11-25 US disclosed
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) 2019-11-07 US disclosed
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2019-01-10 US disclosed
WO-2017132135-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-03 WO disclosed
US-8263657-B2 Blocking neurokinins; using a benzene compound containing hydroxy or acetoxy group; antiinflammatory agents INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-09-11 US disclosed
EP-1888174-B1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER (US) 2012-02-22 EP disclosed
US-8097759-B2 Inflammatory cytokine release inhibitor INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2012-01-17 US disclosed
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR INSTITUTE OF MEDICINAL MOLECULAR DESIGN. INC. (JP) 2010-10-28 US disclosed
EP-1888174-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS Johnson and Johnson Consumer Companies, Inc. (US) 2008-02-20 EP disclosed
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof EASTMAN CHEMICAL COMPANY 2007-11-01 US disclosed
EP-1847263-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-24 EP disclosed
EP-1844766-A2 Inhibitors against the production and release of inflammatory cytokines Institute of Medicinal Molecular Design, Inc. (JP) 2007-10-17 EP disclosed
WO-2006127539-A1 USE OF CHALCONES FOR THE TREATMENT OF VIRAL DISORDERS JOHNSON & JOHNSON CONSUMER COMPANIES, INC. (US) 2006-11-30 WO disclosed
US-20060270614-A1 Use of chalcones for the treatment of viral disorders JOHNSON & JOHNSON CONSUMER COMPANIES, INC. 2006-11-30 US disclosed
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) 2004-12-23 US disclosed
EP-1352650-A1 INHIBITORS AGAINST THE PRODUCTION AND RELEASE OF INFLAMMATORY CYTOKINES Institute of Medicinal Molecular Design, Inc. (JP) 2003-10-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254859-A1 Compounds exhibiting efflux inhibitor activity and composition and uses thereof ABCC4, NCOA4, NR4A3 NR1H4 32/4885MAPT 4566/4885NPC1 362/4885
US-20190337916-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA NOTCH1, DNER, NOTCH2 NR1H4 1212/4885MAPT 4067/4885NPC1 3334/4885
US-20060270614-A1 Use of chalcones for the treatment of viral disorders HAVCR2, HMGB3, EIF2AK2 NR1H4 704/4885MAPT 788/4885NPC1 324/4885
US-20100274051-A1 INFLAMMATORY CYTOKINE RELEASE INHIBITOR IL1B, NFKBIA, IL1A NR1H4 1575/4885MAPT 1849/4885NPC1 896/4885
US-20190008797-A1 ESTROGEN RECEPTOR ALPHA COLIGANDS, AND METHODS OF USE THEREOF ESRRG, GPER1, ESR2 NR1H4 46/4885MAPT 4210/4885NPC1 4155/4885
US-20040259877-A1 Inhibitors against the production and release of inflammatory cytokines NFKBIA, IL1B, IKBKB NR1H4 2138/4885MAPT 2435/4885NPC1 1519/4885
US-20210363121-A1 NOTCH INHIBITORS FOR USE IN THE TREATMENT OF T-CELL ACUTE LYMPHOBLASTIC LEUKEMIA NOTCH1, DNER, NOTCH2 NR1H4 1212/4885MAPT 4067/4885NPC1 3334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.